Cas‐CLOVER‐mediated knockout of STAT1: A novel approach to engineer packaging HEK‐293 cell lines used for rAAV production
Biotechnology Journal · 2024
DOI: 10.1002/biot.202400415 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biotechnology Journal, 2024. Verfasst von Peter Andorfer und 13 weiteren Autor:innen. Beteiligte Einrichtung: Gene Therapy Process Development, Baxalta Innovations GmbH, a part of Takeda companies, Orth an der Donau, Austria. Hauptthemen laut MEDLINE: Dependovirus, STAT1 Transcription Factor, CRISPR-Cas Systems, Gene Editing. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
In addressing the limitations of CRISPR‐Cas9, including off‐target effects and high licensing fees for commercial use, Cas‐CLOVER, a dimeric gene editing tool activated by two guide RNAs, was recently developed. This study focused on implementing and evaluating Cas‐CLOVER in HEK‐293 cells used for recombinant adeno‐associated virus (rAAV) production by targeting the signal transducer and activator of transcription 1 (STAT1) locus, which is crucial for cell growth regulation and might influence rAAV production yields. Cas‐CLOVER demonstrated impressive efficiency in gene editing, achieving over 90% knockout (KO) success. Thirteen selected HEK‐293 STAT1 KO sub‐clones were subjected to extensive analytical characterization to assess their genomic stability, crucial for maintaining cell integrity and functionality. Additionally, rAAV9 productivity, Rep protein pattern profile, and potency, among others, were assessed. Clones showed significant variation in capsid and vector genome titers, with capsid titer reductions ranging from 15% to 98% and vector genome titers from 16% to 55%. Interestingly, the Cas‐CLOVER‐mediated STAT1 KO bulk cell population showed a better ratio of full to empty capsids. Our study also established a comprehensive analytical workflow to detect and evaluate the gene KOs generated by this innovative tool, providing a solid groundwork for future research in precise gene editing technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Gene Therapy Process Development, Baxalta Innovations GmbH, a part of Takeda companies, Orth an der Donau, Austria.
- Demeetra AgBio, Lexington, Kentucky, USA.
- Department of Analytical Chemistry, University of Vienna, Vienna, Austria.
ORCID-Profile: Juan A Hernandez Bort
Zitieren
APA
Andorfer, P., Kahlig, C. I., Pakusic, D., Pachlinger, R., John, C., Schrenk, I., Eisenhut, P., Lengler, J., Innthaler, B., Micutkova, L., Kraus, B., Brizzee, C., Crawford, J., & Hernandez Bort, J. A. (2024). Cas‐CLOVER‐mediated knockout of STAT1: A novel approach to engineer packaging HEK‐293 cell lines used for rAAV production. Biotechnology Journal. https://doi.org/10.1002/biot.202400415
Vancouver
Andorfer P, Kahlig CI, Pakusic D, Pachlinger R, John C, Schrenk I, et al. Cas‐CLOVER‐mediated knockout of STAT1: A novel approach to engineer packaging HEK‐293 cell lines used for rAAV production. Biotechnology Journal. 2024. doi:10.1002/biot.202400415
BibTeX
@article{Andorfer2024,
author = {Andorfer, Peter and Kahlig, Carolin-Isabel and Pakusic, Doris and Pachlinger, Robert and John, Christiane and Schrenk, Irene and Eisenhut, Peter and Lengler, Johannes and Innthaler, Bernd and Micutkova, Lucia and Kraus, Barbara and Brizzee, Corey and Crawford, Jack and Hernandez Bort, Juan A},
title = {Cas‐CLOVER‐mediated knockout of STAT1: A novel approach to engineer packaging HEK‐293 cell lines used for rAAV production},
journal = {Biotechnology Journal},
year = {2024},
doi = {10.1002/biot.202400415}
}
EUVIMED